Albireo Prices $65.0 Million Public Offering of Common Stock

Albireo Pharma (Nasdaq:ALBO) a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,970,000 shares of its common stock at a price to the public of $33.00 per share.
As quoted in the press release:

Albireo’s gross proceeds from this offering are expected to be approximately $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 295,500 shares of common stock on the same terms and conditions.  All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about January 29, 2018, subject to customary closing conditions.

Cowen and William Blair are acting as joint book-running managers and representatives of the underwriters for the offering. Needham & Company, Wedbush PacGrow and Roth Capital Partners are acting as co-managers.

Click here to read the full press release.